Prestige Consumer Healthcare (PBH) Stock Forecast, Price Target & Predictions
PBH Stock Forecast
Prestige Consumer Healthcare stock forecast is as follows: an average price target of $82.00 (represents a 11.13% upside from PBH’s last price of $73.79) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
PBH Price Target
The average price target for Prestige Consumer Healthcare (PBH) is $82.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $93.00 to $71.00. This represents a potential 11.13% upside from PBH's last price of $73.79.
PBH Analyst Ratings
According to 3 Wall Street analysts, Prestige Consumer Healthcare's rating consensus is 'Buy'. The analyst rating breakdown for PBH stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Prestige Consumer Healthcare Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 21, 2024 | Linda Bolton Weiser | D.A. Davidson | $93.00 | $68.13 | 36.51% | 26.03% |
| Nov 17, 2022 | - | Canaccord Genuity | $71.00 | $58.35 | 21.68% | -3.78% |
The latest Prestige Consumer Healthcare stock forecast, released on Jun 21, 2024 by Linda Bolton Weiser from D.A. Davidson, set a price target of $93.00, which represents a 36.51% increase from the stock price at the time of the forecast ($68.13), and a 26.03% increase from PBH last price ($73.79).
Prestige Consumer Healthcare Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $93.00 |
| Last Closing Price | $73.79 | $73.79 | $73.79 |
| Upside/Downside | -100.00% | -100.00% | 26.03% |
In the current month, the average price target of Prestige Consumer Healthcare stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Prestige Consumer Healthcare's last price of $73.79. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 23, 2024 | Jefferies | Buy | Hold | Downgrade |
| Nov 17, 2022 | Canaccord Genuity | - | Buy | Initialise |
| May 10, 2022 | Jefferies | - | Buy | Upgrade |
| May 09, 2022 | Oppenheimer | - | Outperform | Upgrade |
Prestige Consumer Healthcare's last stock rating was published by Jefferies on Sep 23, 2024. The company Downgrade its PBH rating from "Buy" to "Hold".
Prestige Consumer Healthcare Financial Forecast
Prestige Consumer Healthcare Revenue Forecast
| Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $282.74M | $286.32M | $279.31M | $285.87M | $275.52M | $289.27M | $277.06M | $266.94M | $274.47M | $276.23M | $269.18M | $237.76M | $238.79M | $237.42M | $229.39M | $251.24M | $241.55M | $238.07M | $232.15M | $241.03M | $255.97M |
| Avg Forecast | $295.83M | $295.28M | $290.41M | $281.10M | $293.28M | $289.39M | $282.15M | $260.42M | $287.42M | $280.25M | $285.22M | $278.79M | $278.92M | $273.84M | $283.20M | $268.92M | $258.25M | $260.37M | $261.23M | $232.41M | $230.59M | $231.55M | $227.43M | $221.27M | $239.65M | $240.52M | $237.31M | $231.52M | $237.22M | $251.87M |
| High Forecast | $295.83M | $295.28M | $290.41M | $281.10M | $293.28M | $289.39M | $282.27M | $260.48M | $287.42M | $280.25M | $285.41M | $278.79M | $278.92M | $273.84M | $283.20M | $268.92M | $258.25M | $260.37M | $261.23M | $232.41M | $230.59M | $231.55M | $227.43M | $221.27M | $239.65M | $240.52M | $237.31M | $231.52M | $237.22M | $302.25M |
| Low Forecast | $295.83M | $295.28M | $290.41M | $281.10M | $293.28M | $289.39M | $281.99M | $260.36M | $287.42M | $280.25M | $285.09M | $278.79M | $278.92M | $273.84M | $283.20M | $268.92M | $258.25M | $260.37M | $261.23M | $232.41M | $230.59M | $231.55M | $227.43M | $221.27M | $239.65M | $240.52M | $237.31M | $231.52M | $237.22M | $201.50M |
| # Analysts | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.01% | 1.00% | 1.00% | 1.02% | 1.01% | 1.02% | 1.03% | 1.03% | 1.05% | 1.06% | 1.16% | 1.03% | 1.03% | 1.04% | 1.04% | 1.05% | 1.00% | 1.00% | 1.00% | 1.02% | 1.02% |
Prestige Consumer Healthcare's average Quarter revenue forecast for Mar 24 based on 2 analysts is $287.42M, with a low forecast of $287.42M, and a high forecast of $287.42M. PBH's average Quarter revenue forecast represents a 1.66% increase compared to the company's last Quarter revenue of $282.74M (Dec 23).
Prestige Consumer Healthcare EBITDA Forecast
| Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | $91.79M | $93.69M | $91.99M | $95.68M | $94.16M | $91.82M | $94.57M | $83.63M | $90.47M | $83.91M | $99.04M | $66.89M | $81.42M | $80.71M | $87.60M | $80.34M | $82.45M | $75.74M | $78.17M | $-145.71M | $-17.56M |
| Avg Forecast | $99.32M | $99.14M | $97.50M | $94.38M | $98.47M | $97.16M | $94.73M | $87.44M | $101.04M | $94.09M | $95.76M | $93.60M | $91.85M | $87.07M | $95.08M | $90.29M | $83.50M | $87.42M | $87.71M | $78.03M | $66.04M | $77.74M | $76.36M | $74.29M | $71.65M | $80.75M | $79.68M | $77.73M | $-141.55M | $-17.28M |
| High Forecast | $99.32M | $99.14M | $97.50M | $94.38M | $98.47M | $97.16M | $94.77M | $87.46M | $121.25M | $94.09M | $95.82M | $93.60M | $110.22M | $104.49M | $95.08M | $90.29M | $100.20M | $87.42M | $87.71M | $78.03M | $79.24M | $77.74M | $76.36M | $74.29M | $85.99M | $80.75M | $79.68M | $77.73M | $-113.24M | $-13.82M |
| Low Forecast | $99.32M | $99.14M | $97.50M | $94.38M | $98.47M | $97.16M | $94.68M | $87.41M | $80.83M | $94.09M | $95.72M | $93.60M | $73.48M | $69.66M | $95.08M | $90.29M | $66.80M | $87.42M | $87.71M | $78.03M | $52.83M | $77.74M | $76.36M | $74.29M | $57.32M | $80.75M | $79.68M | $77.73M | $-169.86M | $-20.73M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.98% | 0.98% | 0.98% | 1.04% | 1.08% | 0.97% | 1.05% | 1.00% | 1.03% | 0.96% | 1.27% | 1.01% | 1.05% | 1.06% | 1.18% | 1.12% | 1.02% | 0.95% | 1.01% | 1.03% | 1.02% |
2 analysts predict PBH's average Quarter EBITDA for Mar 24 to be $101.04M, with a high of $121.25M and a low of $80.83M. This is 10.08% upper than Prestige Consumer Healthcare's previous annual EBITDA (Dec 23) of $91.79M.
Prestige Consumer Healthcare Net Income Forecast
| Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 |
| Net Income | - | - | - | - | - | - | - | - | - | $53.05M | $53.56M | $53.28M | $-240.55M | $51.95M | $51.02M | $55.27M | $52.09M | $50.22M | $45.33M | $57.76M | $35.51M | $40.87M | $44.59M | $43.71M | $37.05M | $38.06M | $33.25M | $33.92M | $-139.27M | $-39.69M |
| Avg Forecast | $63.34M | $62.33M | $60.15M | $54.12M | $62.30M | $60.58M | $54.52M | $43.20M | $61.61M | $52.32M | $53.65M | $50.74M | $56.01M | $48.33M | $50.35M | $52.19M | $50.92M | $44.40M | $49.60M | $43.56M | $35.06M | $38.56M | $36.05M | $35.19M | $33.04M | $37.70M | $32.92M | $31.97M | $-135.29M | $-39.04M |
| High Forecast | $63.34M | $62.33M | $60.15M | $54.12M | $62.30M | $60.58M | $55.02M | $43.21M | $73.93M | $52.32M | $53.65M | $50.74M | $67.21M | $58.00M | $50.35M | $52.19M | $61.10M | $44.40M | $49.60M | $43.56M | $42.07M | $38.56M | $36.05M | $35.19M | $39.65M | $37.70M | $32.92M | $31.97M | $-108.24M | $-31.23M |
| Low Forecast | $63.34M | $62.33M | $60.15M | $54.12M | $62.30M | $60.58M | $54.02M | $43.19M | $49.29M | $52.32M | $53.65M | $50.74M | $44.81M | $38.67M | $50.35M | $52.19M | $40.73M | $44.40M | $49.60M | $43.56M | $28.05M | $38.56M | $36.05M | $35.19M | $26.43M | $37.70M | $32.92M | $31.97M | $-162.35M | $-46.84M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.01% | 1.00% | 1.05% | -4.30% | 1.07% | 1.01% | 1.06% | 1.02% | 1.13% | 0.91% | 1.33% | 1.01% | 1.06% | 1.24% | 1.24% | 1.12% | 1.01% | 1.01% | 1.06% | 1.03% | 1.02% |
Prestige Consumer Healthcare's average Quarter net income forecast for Mar 24 is $61.61M, with a range of $49.29M to $73.93M. PBH's average Quarter net income forecast represents a 16.14% increase compared to the company's last Quarter net income of $53.05M (Dec 23).
Prestige Consumer Healthcare SG&A Forecast
| Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 |
| SG&A | - | - | - | - | - | - | - | - | - | $65.47M | $66.10M | $63.92M | $58.53M | $56.96M | $70.26M | $66.67M | $64.75M | $66.22M | $72.98M | $61.91M | $60.24M | $59.48M | $58.73M | $47.68M | $63.75M | $54.87M | $61.18M | $56.51M | $55.73M | $157.13M |
| Avg Forecast | $70.06M | $69.93M | $68.77M | $66.57M | $69.45M | $68.53M | $66.82M | $61.67M | $76.58M | $66.37M | $67.54M | $66.02M | $69.62M | $63.74M | $67.07M | $63.69M | $63.29M | $61.66M | $61.86M | $55.04M | $59.47M | $54.83M | $53.86M | $52.40M | $56.86M | $56.96M | $56.20M | $54.83M | $54.14M | $154.56M |
| High Forecast | $70.06M | $69.93M | $68.77M | $66.57M | $69.45M | $68.53M | $66.85M | $61.69M | $91.90M | $66.37M | $67.59M | $66.02M | $83.54M | $76.49M | $67.07M | $63.69M | $75.95M | $61.66M | $61.86M | $55.04M | $71.36M | $54.83M | $53.86M | $52.40M | $68.23M | $56.96M | $56.20M | $54.83M | $64.97M | $185.47M |
| Low Forecast | $70.06M | $69.93M | $68.77M | $66.57M | $69.45M | $68.53M | $66.78M | $61.66M | $61.26M | $66.37M | $67.51M | $66.02M | $55.70M | $50.99M | $67.07M | $63.69M | $50.63M | $61.66M | $61.86M | $55.04M | $47.57M | $54.83M | $53.86M | $52.40M | $45.49M | $56.96M | $56.20M | $54.83M | $43.31M | $123.65M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.99% | 0.98% | 0.97% | 0.84% | 0.89% | 1.05% | 1.05% | 1.02% | 1.07% | 1.18% | 1.12% | 1.01% | 1.08% | 1.09% | 0.91% | 1.12% | 0.96% | 1.09% | 1.03% | 1.03% | 1.02% |
Prestige Consumer Healthcare's average Quarter SG&A projection for Mar 24 is $76.58M, based on 2 Wall Street analysts, with a range of $61.26M to $91.90M. The forecast indicates a 16.97% rise compared to PBH last annual SG&A of $65.47M (Dec 23).
Prestige Consumer Healthcare EPS Forecast
| Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | $1.07 | $1.08 | $1.07 | $-4.83 | $1.05 | $1.02 | $1.10 | $1.03 | $1.00 | $0.90 | $1.15 | $0.71 | $0.81 | $0.89 | $0.87 | $0.74 | $0.76 | $0.66 | $0.66 | $-2.68 | $-0.75 |
| Avg Forecast | $1.26 | $1.24 | $1.20 | $1.08 | $1.24 | $1.21 | $1.08 | $0.86 | $1.14 | $1.04 | $1.07 | $1.01 | $1.04 | $1.01 | $1.00 | $1.04 | $0.89 | $0.88 | $0.99 | $0.87 | $0.78 | $0.77 | $0.72 | $0.70 | $0.74 | $0.75 | $0.66 | $0.64 | $0.70 | $0.60 |
| High Forecast | $1.26 | $1.24 | $1.20 | $1.08 | $1.24 | $1.21 | $1.09 | $0.86 | $1.14 | $1.04 | $1.07 | $1.01 | $1.04 | $1.01 | $1.00 | $1.04 | $0.89 | $0.88 | $0.99 | $0.87 | $0.78 | $0.77 | $0.72 | $0.70 | $0.74 | $0.75 | $0.66 | $0.64 | $0.70 | $0.72 |
| Low Forecast | $1.26 | $1.24 | $1.20 | $1.08 | $1.24 | $1.21 | $1.07 | $0.86 | $1.14 | $1.04 | $1.07 | $1.01 | $1.04 | $1.01 | $1.00 | $1.04 | $0.89 | $0.88 | $0.99 | $0.87 | $0.78 | $0.77 | $0.72 | $0.70 | $0.74 | $0.75 | $0.66 | $0.64 | $0.70 | $0.48 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.03% | 1.01% | 1.06% | -4.65% | 1.04% | 1.02% | 1.06% | 1.16% | 1.13% | 0.91% | 1.33% | 0.91% | 1.06% | 1.24% | 1.24% | 1.01% | 1.01% | 1.01% | 1.04% | -3.81% | -1.25% |
According to 2 Wall Street analysts, Prestige Consumer Healthcare's projected average Quarter EPS for Mar 24 is $1.14, with a low estimate of $1.14 and a high estimate of $1.14. This represents a 6.46% increase compared to PBH previous annual EPS of $1.07 (Dec 23).
Prestige Consumer Healthcare Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PCRX | Pacira BioSciences | $16.45 | $40.00 | 143.16% | Hold |
| EVO | Evotec SE | $4.40 | $8.00 | 81.82% | Buy |
| ANIP | ANI Pharmaceuticals | $56.01 | $79.00 | 41.05% | Buy |
| AMPH | Amphastar Pharmaceuticals | $50.59 | $66.00 | 30.46% | Buy |
| COLL | Collegium Pharmaceutical | $32.72 | $41.50 | 26.83% | Buy |
| PBH | Prestige Consumer Healthcare | $73.79 | $82.00 | 11.13% | Buy |
| SUPN | Supernus Pharmaceuticals | $34.70 | $38.00 | 9.51% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| PAHC | Phibro Animal Health | $22.37 | $18.67 | -16.54% | Buy |
PBH Forecast FAQ
Is Prestige Consumer Healthcare a good buy?
Yes, according to 3 Wall Street analysts, Prestige Consumer Healthcare (PBH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of PBH's total ratings.
What is PBH's price target?
Prestige Consumer Healthcare (PBH) average price target is $82 with a range of $71 to $93, implying a 11.13% from its last price of $73.79. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Prestige Consumer Healthcare stock go up soon?
According to Wall Street analysts' prediction for PBH stock, the company can go up by 11.13% (from the last price of $73.79 to the average price target of $82), up by 26.03% based on the highest stock price target, and down by -3.78% based on the lowest stock price target.
Can Prestige Consumer Healthcare stock reach $110?
PBH's average twelve months analyst stock price target of $82 does not support the claim that Prestige Consumer Healthcare can reach $110 in the near future.
What are Prestige Consumer Healthcare's analysts' financial forecasts?
Prestige Consumer Healthcare's analysts financial forecasts for the fiscal year (Mar 2025) are as follows: average revenue is $1.13B (high $1.13B, low $1.13B), average EBITDA is $377.79M (high $377.86M, low $377.72M), average net income is $220.59M (high $221.11M, low $220.08M), average SG&A $266.48M (high $266.52M, low $266.43M), and average EPS is $4.39 (high $4.4, low $4.38). PBH's analysts financial forecasts for the fiscal year (Mar 2026) are as follows: average revenue is $1.16B (high $1.16B, low $1.16B), average EBITDA is $390.35M (high $390.35M, low $390.35M), average net income is $239.94M (high $239.94M, low $239.94M), average SG&A $275.33M (high $275.33M, low $275.33M), and average EPS is $4.77 (high $4.77, low $4.77).
Did the PBH's actual financial results beat the analysts' financial forecasts?
Based on Prestige Consumer Healthcare's last annual report (Mar 2023), the company's revenue was $1.13B, beating the average analysts forecast of $1.1B by 2.07%. Apple's EBITDA was $378.09M, beating the average prediction of $364.3M by 3.79%. The company's net income was $-82.306M, missing the average estimation of $206.88M by -139.78%. Apple's SG&A was $252.42M, missing the average forecast of $264.11M by -4.43%. Lastly, the company's EPS was $-1.65, missing the average prediction of $4.09 by -140.32%. In terms of the last quarterly report (Dec 2023), Prestige Consumer Healthcare's revenue was $282.74M, beating the average analysts' forecast of $280.25M by 0.89%. The company's EBITDA was $91.79M, missing the average prediction of $94.09M by -2.45%. Prestige Consumer Healthcare's net income was $53.05M, beating the average estimation of $52.32M by 1.38%. The company's SG&A was $65.47M, missing the average forecast of $66.37M by -1.36%. Lastly, the company's EPS was $1.07, beating the average prediction of $1.04 by 2.80%